We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SEC Advisory Panel May Have Little Influence on Sarbanes-Oxley Decisions
SEC Advisory Panel May Have Little Influence on Sarbanes-Oxley Decisions
April 21, 2006
An SEC advisory committee has overwhelmingly recommended that the agency grant relief from Sarbanes-Oxley (SOX) reporting and auditing requirements for small companies, but the panel does not have the influence on the SEC that the pharmaceutical and biotechnology industries may believe, an agency spokesman says.